期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌靶向药物的最新进展 被引量：9

原文传递
导出
摘要 随着分子生物学研究进展，靶向治疗已经进入一个新的时代。分子靶向治疗作为乳腺癌治疗的新领域已被广为重视。这些药物包括抗HER-2靶向药物、血管生成抑制剂、酪氨酸激酶抑制剂、聚ADP-核糖聚合酶（poly—ADP—ribose polymerase，PARP）抑制剂等。这些靶向药物的涌现不仅丰富了乳腺癌治疗的理论和实践，而且改变了临床治疗的思维模式和行为模式。本文主要对乳腺癌分子靶向药物的最新进展作一综述。
作者 邱梅清 佟仲生
机构地区 天津医科大学附属肿瘤医院乳腺内科乳腺癌防治教育部重点实验室天津市"肿瘤防治"重点实验室
出处 《中华乳腺病杂志（电子版）》 CAS 2013年第1期42-46,共5页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 乳腺肿瘤 靶向治疗 曲妥珠单克隆抗体
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献33

  • 1Procter M, Surer T, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial[ J]. J Clin Oncol, 2010, 28(21 ) : 3422-3428. 被引量：1
  • 2Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trim comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 [J]. J Clin Oncol, 2005,23(31 ) : 7811-7819. 被引量：1
  • 3Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials [ J]. J Clin Oncol, 2010, 28 (21) :3416-3421. 被引量：1
  • 4Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab ( AC- TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu-positive early breast cancer patients: BCIRG 006 study [ J ]. Cancer Res, 2009,69 (24 suppl) : nr 62. 被引量：1
  • 5Joensuu H, Bono P, Kataja V, et al. Fluorouacil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol,2009,27(34) : 5685-5692. 被引量：1
  • 6Wolff A C, Wang M, Li H, et al. Phase H trial of pegylated liposomal doxorubicin plus doeetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trim E3198 [J]. Breast Cancer Res Treat, 2010, 121(1) :111-120. 被引量：1
  • 7Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer, phase II study of the Hellenic Cooperative Oncology Group ( HeCOG ) with biomarker evaluation [ J ]. Oncology, 2009,76 (4) :275-285. 被引量：1
  • 8Inane K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus doeetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group [ J]. Breast Cancer Res Treat, 2010, 119(1) :127-136. 被引量：1
  • 9Kmp IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drag conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(16) :2698-2704. 被引量：1
  • 10Bun'is HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 ( HER2 ) -positive breast cancer after prior HER2-directed therapy [ J ]. J Clin Oncol, 2011,29(4) :398-405. 被引量：1

共引文献3

同被引文献99

引证文献9

二级引证文献28

中华乳腺病杂志（电子版）
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部